A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Latest Information Update: 12 Aug 2024
At a glance
- Drugs Pegcetacoplan (Primary)
- Indications Glomerulonephritis; Membranous glomerulonephritis
- Focus Registrational; Therapeutic Use
- Acronyms VALIANT
- Sponsors Apellis Pharmaceuticals
- 08 Aug 2024 According to an Apellis Pharmaceuticals media release,announced positive topline results from this trial.
- 08 Aug 2024 According to an Apellis Pharmaceuticals media release,Apellis will host a conference call with Andrew Bomback , principal investigator for the VALIANT study to discuss the Phase 3 VALIANT results on Thursday, August 8 at 8:00 a.m.
- 08 Aug 2024 According to an Apellis Pharmaceuticals media release, the company plans to submit a supplemental new drug application to the U.S. Food and Drug Administration in early 2025.